Hyundai Pharmaceutical Co., Ltd. (004310.KS)
KRW 3710.0
(-2.62%)
KRW 3710.0
(-2.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 6.12 Billion KRW | 3819.55% |
| 2022 | -164.58 Million KRW | 94.81% |
| 2021 | -3.17 Billion KRW | -245.09% |
| 2020 | 2.18 Billion KRW | 80.32% |
| 2019 | 1.21 Billion KRW | 157.58% |
| 2018 | -2.1 Billion KRW | -244.43% |
| 2017 | 1.45 Billion KRW | 15.66% |
| 2016 | 1.26 Billion KRW | -20.89% |
| 2015 | 1.59 Billion KRW | 8.55% |
| 2014 | 1.46 Billion KRW | 3.77% |
| 2013 | 1.41 Billion KRW | 129.17% |
| 2012 | -4.84 Billion KRW | -590.11% |
| 2011 | 989.54 Million KRW | -66.66% |
| 2010 | 2.96 Billion KRW | 77.67% |
| 2009 | 1.67 Billion KRW | -51.93% |
| 2008 | 3.47 Billion KRW | -64.31% |
| 2007 | 9.73 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 1.08 Billion KRW | 249.89% |
| 2024 Q3 | -487.44 Million KRW | -145.06% |
| 2024 Q1 | 309.18 Million KRW | 348.82% |
| 2023 Q3 | 1.74 Billion KRW | -43.51% |
| 2023 Q2 | 3.09 Billion KRW | 85.12% |
| 2023 Q1 | 1.67 Billion KRW | 127.13% |
| 2023 Q4 | 68.88 Million KRW | -96.06% |
| 2023 FY | 6.12 Billion KRW | 3819.55% |
| 2022 Q3 | 2.41 Billion KRW | 0.58% |
| 2022 FY | -164.58 Million KRW | 94.81% |
| 2022 Q4 | -6.16 Billion KRW | -354.75% |
| 2022 Q2 | 2.4 Billion KRW | 104.87% |
| 2022 Q1 | 1.17 Billion KRW | 148.59% |
| 2021 Q2 | 436.04 Million KRW | 145.26% |
| 2021 Q3 | -229.65 Million KRW | -152.67% |
| 2021 Q1 | -963.41 Million KRW | -2116.62% |
| 2021 FY | -3.17 Billion KRW | -245.09% |
| 2021 Q4 | -2.41 Billion KRW | -952.07% |
| 2020 Q1 | 143.93 Million KRW | 391.81% |
| 2020 Q4 | 47.77 Million KRW | 105.19% |
| 2020 Q2 | 2.91 Billion KRW | 1925.74% |
| 2020 Q3 | -920.01 Million KRW | -131.55% |
| 2020 FY | 2.18 Billion KRW | 80.32% |
| 2019 Q3 | 221.53 Million KRW | -63.36% |
| 2019 FY | 1.21 Billion KRW | 157.58% |
| 2019 Q2 | 604.58 Million KRW | 38.65% |
| 2019 Q4 | -49.32 Million KRW | -122.27% |
| 2019 Q1 | 436.05 Million KRW | 113.18% |
| 2018 Q1 | 412.81 Million KRW | 27.62% |
| 2018 Q2 | 486.01 Million KRW | 17.73% |
| 2018 Q3 | 302.19 Million KRW | -37.82% |
| 2018 FY | -2.1 Billion KRW | -244.43% |
| 2018 Q4 | -3.3 Billion KRW | -1194.46% |
| 2017 FY | 1.45 Billion KRW | 15.66% |
| 2017 Q4 | 323.45 Million KRW | 13.84% |
| 2017 Q3 | 284.13 Million KRW | -40.96% |
| 2017 Q2 | 481.27 Million KRW | 30.26% |
| 2017 Q1 | 369.47 Million KRW | 96.76% |
| 2016 Q1 | 350.4 Million KRW | -37.47% |
| 2016 Q2 | 472.15 Million KRW | 34.75% |
| 2016 Q4 | 187.77 Million KRW | -24.8% |
| 2016 Q3 | 249.72 Million KRW | -47.11% |
| 2016 FY | 1.26 Billion KRW | -20.89% |
| 2015 Q1 | 253.1 Million KRW | -43.88% |
| 2015 FY | 1.59 Billion KRW | 8.55% |
| 2015 Q4 | 560.37 Million KRW | 126.56% |
| 2015 Q3 | 247.33 Million KRW | -53.59% |
| 2015 Q2 | 532.97 Million KRW | 110.58% |
| 2014 Q2 | 395.51 Million KRW | -24.54% |
| 2014 Q1 | 524.13 Million KRW | 359.18% |
| 2014 Q4 | 450.98 Million KRW | 31.77% |
| 2014 FY | 1.46 Billion KRW | 3.77% |
| 2014 Q3 | 342.26 Million KRW | -13.46% |
| 2013 Q1 | 476.45 Million KRW | 199.12% |
| 2013 Q2 | 610.94 Million KRW | 28.23% |
| 2013 Q3 | 529.7 Million KRW | -13.3% |
| 2013 Q4 | -202.22 Million KRW | -138.18% |
| 2013 FY | 1.41 Billion KRW | 129.17% |
| 2012 Q3 | -1.14 Billion KRW | 66.41% |
| 2012 FY | -4.84 Billion KRW | -590.11% |
| 2012 Q1 | 244.14 Million KRW | -55.74% |
| 2012 Q2 | -3.4 Billion KRW | -1494.43% |
| 2012 Q4 | -480.68 Million KRW | 57.97% |
| 2011 FY | 989.54 Million KRW | -66.66% |
| 2011 Q1 | 1.46 Billion KRW | 366.26% |
| 2011 Q2 | -253.98 Million KRW | -117.36% |
| 2011 Q3 | -771.31 Million KRW | -203.69% |
| 2011 Q4 | 551.6 Million KRW | 171.52% |
| 2010 Q3 | 2.82 Billion KRW | 987.65% |
| 2010 Q1 | 434.57 Million KRW | -57.11% |
| 2010 Q4 | -549.55 Million KRW | -119.46% |
| 2010 FY | 2.96 Billion KRW | 77.67% |
| 2010 Q2 | 259.59 Million KRW | -40.26% |
| 2009 FY | 1.67 Billion KRW | -51.93% |
| 2009 Q4 | 1.01 Billion KRW | 1107.64% |
| 2009 Q3 | 83.89 Million KRW | -59.3% |
| 2009 Q2 | 206.1 Million KRW | -43.92% |
| 2009 Q1 | 367.48 Million KRW | -57.75% |
| 2008 Q3 | -1.95 Billion KRW | -183.21% |
| 2008 Q4 | 869.85 Million KRW | 144.39% |
| 2008 Q2 | 2.35 Billion KRW | 6.55% |
| 2008 Q1 | 2.21 Billion KRW | -14.59% |
| 2008 FY | 3.47 Billion KRW | -64.31% |
| 2007 Q2 | 2.4 Billion KRW | 18.1% |
| 2007 FY | 9.73 Billion KRW | 0.0% |
| 2007 Q3 | 2.71 Billion KRW | 12.78% |
| 2007 Q4 | 2.58 Billion KRW | -4.52% |
| 2007 Q1 | 2.03 Billion KRW | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 185.251% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 89.443% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 110.274% |
| HANDOK Inc. | -28.79 Billion KRW | 121.258% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 172.747% |
| Yuhan Corporation | 93.5 Billion KRW | 93.453% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | 44.96% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 124.673% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 95.814% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -74.478% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 344.244% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 395.18% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 235.292% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | 72.588% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 185.251% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 129.234% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -70.838% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 105.176% |
| JW Holdings Corporation | 19.02 Billion KRW | 67.825% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 107.756% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 97.119% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 83.458% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 110.679% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -267.996% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -22.319% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 185.251% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | 83.439% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 94.51% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 83.458% |
| Yuhan Corporation | 93.5 Billion KRW | 93.453% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 137.673% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 257.959% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -0.041% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 83.458% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | 67.62% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 87.315% |
| CKD Bio Corp. | -24.19 Billion KRW | 125.304% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | 74.404% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | 77.689% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | 79.439% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 110.679% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 86.977% |
| Boryung Corporation | 40.2 Billion KRW | 84.773% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 119.54% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 344.244% |
| JW Lifescience Corporation | 28.14 Billion KRW | 78.248% |